[144] Global-E Online Ltd. SEC Filing
Lifecore Biomedical (LFCR) 鈥� CFO insider equity transaction
On 07/08/2025, Chief Financial Officer Ryan D. Lake reported the vesting of 75,000 performance-based restricted stock units (RSUs). The units converted into common shares (Form 4, code M), lifting his direct holdings to 392,429 shares.
To satisfy statutory tax withholding, the issuer automatically withheld 32,806 shares at $8.19 per share (code F). After this offset, Lake鈥檚 direct ownership stands at 359,623 shares, a net increase of roughly 42 k shares versus the pre-transaction level. He also retains 600,000 unexercised performance-based RSUs that continue to vest through 09/03/2029 once additional share-price milestones are achieved.
The filing reflects routine equity-compensation settlement rather than an open-market purchase or discretionary sale. Nonetheless, the additional shares keep the CFO鈥檚 incentives aligned with shareholder value creation.
Lifecore Biomedical (LFCR) 鈥� Transazione interna di azioni da parte del CFO
Il 07/08/2025, il Chief Financial Officer Ryan D. Lake ha comunicato il vesting di 75.000 unit脿 azionarie vincolate basate sulle performance (RSU). Le unit脿 si sono convertite in azioni ordinarie (Modulo 4, codice M), portando la sua partecipazione diretta a 392.429 azioni.
Per adempiere alla ritenuta fiscale obbligatoria, l鈥檈mittente ha trattenuto automaticamente 32.806 azioni a 8,19 $ per azione (codice F). Dopo questa compensazione, la propriet脿 diretta di Lake 猫 pari a 359.623 azioni, con un aumento netto di circa 42.000 azioni rispetto al livello precedente alla transazione. Mantiene inoltre 600.000 RSU basate sulle performance non esercitate che continueranno a maturare fino al 03/09/2029 al raggiungimento di ulteriori obiettivi di prezzo delle azioni.
La comunicazione riflette una normale liquidazione di compensi in azioni e non un acquisto sul mercato aperto o una vendita discrezionale. Tuttavia, le azioni aggiuntive mantengono allineati gli incentivi del CFO con la creazione di valore per gli azionisti.
Lifecore Biomedical (LFCR) 鈥� Transacci贸n interna de acciones del CFO
El 07/08/2025, el Director Financiero Ryan D. Lake inform贸 la consolidaci贸n de 75,000 unidades restringidas basadas en desempe帽o (RSU). Las unidades se convirtieron en acciones comunes (Formulario 4, c贸digo M), elevando su participaci贸n directa a 392,429 acciones.
Para cumplir con la retenci贸n fiscal legal, el emisor retuvo autom谩ticamente 32,806 acciones a $8.19 por acci贸n (c贸digo F). Tras esta deducci贸n, la propiedad directa de Lake es de 359,623 acciones, un aumento neto de aproximadamente 42,000 acciones respecto al nivel previo a la transacci贸n. Adem谩s, conserva 600,000 RSU basadas en desempe帽o no ejercidas que seguir谩n consolid谩ndose hasta el 03/09/2029 al alcanzar nuevos hitos en el precio de la acci贸n.
La presentaci贸n refleja una liquidaci贸n rutinaria de compensaci贸n en acciones y no una compra en el mercado abierto ni una venta discrecional. No obstante, las acciones adicionales mantienen alineados los incentivos del CFO con la creaci贸n de valor para los accionistas.
Lifecore Biomedical (LFCR) 鈥� CFO 雮措秬 欤检嫕 瓯半灅
2025雲� 8鞗� 7鞚�, 斓滉碃鞛毂呾瀯鞛� 霛检澊鞏� D. 霠堨澊韥�臧赌 靹标臣 旮半皹 鞝滍暅 欤检嫕 雼渼(RSU) 75,000臧�鞚� 氩犾姢韺呾潉 氤搓碃頄堨姷雼堧嫟. 頃措嫻 雼渼電� 氤错喌欤茧 鞝勴櫂霅橃棃鞙茧┌(鞏戩嫕 4, 旖旊摐 M), 攴胳潣 歆侅爲 氤挫湢 欤检嫕 靾橂姅 392,429欤�搿� 歃濌岸捻枅鞀惦媹雼�.
氩曥爼 靹戈笀 鞗愳矞歆曥垬毳� 於╈”頃橁赴 鞙勴暣 氚滍枆靷姅 鞛愲彊鞙茧 32,806欤茧ゼ 欤茧嫻 $8.19鞐� 鞗愳矞歆曥垬頄堨姷雼堧嫟(旖旊摐 F). 鞚� 臁办爼 頉� 霠堨澊韥潣 歆侅爲 靻岇湢 欤检嫕鞚� 359,623欤�搿�, 瓯半灅 鞝� 靾橃 雽�牍� 鞎� 42,000欤� 靾滌臧赌頄堨姷雼堧嫟. 攴鸽姅 霕愴暅 600,000臧滌潣 氙疙枆靷� 靹标臣 旮半皹 RSU毳� 氤挫湢頃橁碃 鞛堨溂氅�, 於旉岸� 欤缄岸� 氇╉憸 雼劚 鞁� 2029雲� 9鞗� 3鞚缄箤歆� 瓿勳啀 氩犾姢韺呺惄雼堧嫟.
鞚措矆 鞁犼碃電� 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬雮� 鞛勳潣 毵る弰臧赌 鞎勲媽 鞚检儊鞝侅澑 欤检嫕 氤挫儊 鞝曥偘鞚� 氚橃榿頃╇媹雼�. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 於旉岸� 欤检嫕鞚� CFO鞚� 鞚胳劶韹半笇臧赌 欤检＜ 臧赌旃� 彀届稖瓿� 鞚检箻頃橂弰搿� 鞙犾頃╇媹雼�.
Lifecore Biomedical (LFCR) 鈥� Transaction d鈥檃ctions initi茅e par le CFO
Le 07/08/2025, le Directeur Financier Ryan D. Lake a d茅clar茅 la lev茅e de 75 000 unit茅s d鈥檃ctions restreintes bas茅es sur la performance (RSU). Ces unit茅s se sont converties en actions ordinaires (Formulaire 4, code M), portant sa d茅tention directe 脿 392 429 actions.
Pour satisfaire 脿 la retenue fiscale obligatoire, l鈥櫭﹎etteur a automatiquement retenu 32 806 actions au prix de 8,19 $ par action (code F). Apr猫s cette compensation, la d茅tention directe de Lake s鈥櫭﹍猫ve 脿 359 623 actions, soit une augmentation nette d鈥檈nviron 42 000 actions par rapport au niveau pr茅c茅dent la transaction. Il conserve 茅galement 600 000 RSU bas茅es sur la performance non exerc茅es qui continueront 脿 se lib茅rer jusqu鈥檃u 03/09/2029 sous r茅serve de l鈥檃tteinte de nouveaux objectifs de cours.
Le d茅p么t refl猫te un r猫glement habituel de r茅mun茅ration en actions plut么t qu鈥檜n achat sur le march茅 ouvert ou une vente discr茅tionnaire. N茅anmoins, ces actions suppl茅mentaires maintiennent les incitations du CFO align茅es avec la cr茅ation de valeur pour les actionnaires.
Lifecore Biomedical (LFCR) 鈥� Insider-Aktientransaktion des CFO
Am 07.08.2025 meldete der Finanzvorstand Ryan D. Lake das Vesting von 75.000 leistungsabh盲ngigen Restricted Stock Units (RSUs). Die Einheiten wurden in Stammaktien umgewandelt (Formular 4, Code M), wodurch sein Direktbesitz auf 392.429 Aktien anstieg.
Zur Erf眉llung der gesetzlichen Steuerabz眉ge behielt der Emittent automatisch 32.806 Aktien zu 8,19 $ pro Aktie ein (Code F). Nach diesem Abzug bel盲uft sich Lakes Direktbesitz auf 359.623 Aktien, was einem Nettomehr von etwa 42.000 Aktien gegen眉ber dem Stand vor der Transaktion entspricht. Zudem h盲lt er 600.000 nicht ausge眉bte leistungsabh盲ngige RSUs, die bis zum 03.09.2029 weiter vesten, sobald weitere Kursziele erreicht werden.
Die Meldung spiegelt eine routinem盲脽ige Abwicklung von Aktienverg眉tungen wider und stellt keinen Kauf am offenen Markt oder einen diskretion盲ren Verkauf dar. Dennoch sorgen die zus盲tzlichen Aktien daf眉r, dass die Anreize des CFO mit der Wertsch枚pfung f眉r die Aktion盲re in Einklang bleiben.
- CFO鈥檚 direct ownership rises by 42,194 shares, enhancing alignment with shareholders.
- 600,000 performance-based RSUs remain outstanding, tying future compensation to share-price performance.
- Shares were acquired via vesting, not open-market purchase, reducing the traditional bullish signal strength.
- 32,806 shares were withheld for taxes, representing an immediate disposal rather than a long-term holding increase.
Insights
TL;DR: Vesting of 75 k RSUs; net 42 k share increase; compensation-driven, not open-market, so largely neutral for LFCR.
The Form 4 shows a standard performance-based award converting into stock. Code M indicates automatic conversion, not a cash purchase, limiting its traditional 鈥榖ullish鈥� insider-buy signal. The simultaneous code F disposition is a tax-withholding mechanism, not a discretionary sale. Post-transaction, Lake still owns 359,623 shares and 600,000 unvested RSUs that hinge on future price milestones, providing continued performance alignment. From a governance standpoint, the event neither increases float materially nor signals management sentiment beyond compensation norms; therefore, it is neutral in market impact.
Lifecore Biomedical (LFCR) 鈥� Transazione interna di azioni da parte del CFO
Il 07/08/2025, il Chief Financial Officer Ryan D. Lake ha comunicato il vesting di 75.000 unit脿 azionarie vincolate basate sulle performance (RSU). Le unit脿 si sono convertite in azioni ordinarie (Modulo 4, codice M), portando la sua partecipazione diretta a 392.429 azioni.
Per adempiere alla ritenuta fiscale obbligatoria, l鈥檈mittente ha trattenuto automaticamente 32.806 azioni a 8,19 $ per azione (codice F). Dopo questa compensazione, la propriet脿 diretta di Lake 猫 pari a 359.623 azioni, con un aumento netto di circa 42.000 azioni rispetto al livello precedente alla transazione. Mantiene inoltre 600.000 RSU basate sulle performance non esercitate che continueranno a maturare fino al 03/09/2029 al raggiungimento di ulteriori obiettivi di prezzo delle azioni.
La comunicazione riflette una normale liquidazione di compensi in azioni e non un acquisto sul mercato aperto o una vendita discrezionale. Tuttavia, le azioni aggiuntive mantengono allineati gli incentivi del CFO con la creazione di valore per gli azionisti.
Lifecore Biomedical (LFCR) 鈥� Transacci贸n interna de acciones del CFO
El 07/08/2025, el Director Financiero Ryan D. Lake inform贸 la consolidaci贸n de 75,000 unidades restringidas basadas en desempe帽o (RSU). Las unidades se convirtieron en acciones comunes (Formulario 4, c贸digo M), elevando su participaci贸n directa a 392,429 acciones.
Para cumplir con la retenci贸n fiscal legal, el emisor retuvo autom谩ticamente 32,806 acciones a $8.19 por acci贸n (c贸digo F). Tras esta deducci贸n, la propiedad directa de Lake es de 359,623 acciones, un aumento neto de aproximadamente 42,000 acciones respecto al nivel previo a la transacci贸n. Adem谩s, conserva 600,000 RSU basadas en desempe帽o no ejercidas que seguir谩n consolid谩ndose hasta el 03/09/2029 al alcanzar nuevos hitos en el precio de la acci贸n.
La presentaci贸n refleja una liquidaci贸n rutinaria de compensaci贸n en acciones y no una compra en el mercado abierto ni una venta discrecional. No obstante, las acciones adicionales mantienen alineados los incentivos del CFO con la creaci贸n de valor para los accionistas.
Lifecore Biomedical (LFCR) 鈥� CFO 雮措秬 欤检嫕 瓯半灅
2025雲� 8鞗� 7鞚�, 斓滉碃鞛毂呾瀯鞛� 霛检澊鞏� D. 霠堨澊韥�臧赌 靹标臣 旮半皹 鞝滍暅 欤检嫕 雼渼(RSU) 75,000臧�鞚� 氩犾姢韺呾潉 氤搓碃頄堨姷雼堧嫟. 頃措嫻 雼渼電� 氤错喌欤茧 鞝勴櫂霅橃棃鞙茧┌(鞏戩嫕 4, 旖旊摐 M), 攴胳潣 歆侅爲 氤挫湢 欤检嫕 靾橂姅 392,429欤�搿� 歃濌岸捻枅鞀惦媹雼�.
氩曥爼 靹戈笀 鞗愳矞歆曥垬毳� 於╈”頃橁赴 鞙勴暣 氚滍枆靷姅 鞛愲彊鞙茧 32,806欤茧ゼ 欤茧嫻 $8.19鞐� 鞗愳矞歆曥垬頄堨姷雼堧嫟(旖旊摐 F). 鞚� 臁办爼 頉� 霠堨澊韥潣 歆侅爲 靻岇湢 欤检嫕鞚� 359,623欤�搿�, 瓯半灅 鞝� 靾橃 雽�牍� 鞎� 42,000欤� 靾滌臧赌頄堨姷雼堧嫟. 攴鸽姅 霕愴暅 600,000臧滌潣 氙疙枆靷� 靹标臣 旮半皹 RSU毳� 氤挫湢頃橁碃 鞛堨溂氅�, 於旉岸� 欤缄岸� 氇╉憸 雼劚 鞁� 2029雲� 9鞗� 3鞚缄箤歆� 瓿勳啀 氩犾姢韺呺惄雼堧嫟.
鞚措矆 鞁犼碃電� 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬雮� 鞛勳潣 毵る弰臧赌 鞎勲媽 鞚检儊鞝侅澑 欤检嫕 氤挫儊 鞝曥偘鞚� 氚橃榿頃╇媹雼�. 攴鸽熂鞐愲弰 攵堦惮頃橁碃 於旉岸� 欤检嫕鞚� CFO鞚� 鞚胳劶韹半笇臧赌 欤检＜ 臧赌旃� 彀届稖瓿� 鞚检箻頃橂弰搿� 鞙犾頃╇媹雼�.
Lifecore Biomedical (LFCR) 鈥� Transaction d鈥檃ctions initi茅e par le CFO
Le 07/08/2025, le Directeur Financier Ryan D. Lake a d茅clar茅 la lev茅e de 75 000 unit茅s d鈥檃ctions restreintes bas茅es sur la performance (RSU). Ces unit茅s se sont converties en actions ordinaires (Formulaire 4, code M), portant sa d茅tention directe 脿 392 429 actions.
Pour satisfaire 脿 la retenue fiscale obligatoire, l鈥櫭﹎etteur a automatiquement retenu 32 806 actions au prix de 8,19 $ par action (code F). Apr猫s cette compensation, la d茅tention directe de Lake s鈥櫭﹍猫ve 脿 359 623 actions, soit une augmentation nette d鈥檈nviron 42 000 actions par rapport au niveau pr茅c茅dent la transaction. Il conserve 茅galement 600 000 RSU bas茅es sur la performance non exerc茅es qui continueront 脿 se lib茅rer jusqu鈥檃u 03/09/2029 sous r茅serve de l鈥檃tteinte de nouveaux objectifs de cours.
Le d茅p么t refl猫te un r猫glement habituel de r茅mun茅ration en actions plut么t qu鈥檜n achat sur le march茅 ouvert ou une vente discr茅tionnaire. N茅anmoins, ces actions suppl茅mentaires maintiennent les incitations du CFO align茅es avec la cr茅ation de valeur pour les actionnaires.
Lifecore Biomedical (LFCR) 鈥� Insider-Aktientransaktion des CFO
Am 07.08.2025 meldete der Finanzvorstand Ryan D. Lake das Vesting von 75.000 leistungsabh盲ngigen Restricted Stock Units (RSUs). Die Einheiten wurden in Stammaktien umgewandelt (Formular 4, Code M), wodurch sein Direktbesitz auf 392.429 Aktien anstieg.
Zur Erf眉llung der gesetzlichen Steuerabz眉ge behielt der Emittent automatisch 32.806 Aktien zu 8,19 $ pro Aktie ein (Code F). Nach diesem Abzug bel盲uft sich Lakes Direktbesitz auf 359.623 Aktien, was einem Nettomehr von etwa 42.000 Aktien gegen眉ber dem Stand vor der Transaktion entspricht. Zudem h盲lt er 600.000 nicht ausge眉bte leistungsabh盲ngige RSUs, die bis zum 03.09.2029 weiter vesten, sobald weitere Kursziele erreicht werden.
Die Meldung spiegelt eine routinem盲脽ige Abwicklung von Aktienverg眉tungen wider und stellt keinen Kauf am offenen Markt oder einen diskretion盲ren Verkauf dar. Dennoch sorgen die zus盲tzlichen Aktien daf眉r, dass die Anreize des CFO mit der Wertsch枚pfung f眉r die Aktion盲re in Einklang bleiben.
FAQ
How many LFCR shares did CFO Ryan Lake acquire on 07/08/2025?
What is Ryan Lake鈥檚 current direct ownership in Lifecore Biomedical?
Why were 32,806 LFCR shares disposed of in the filing?
What does the 600,000 figure in the derivative table represent?
Does this Form 4 signal an open-market insider purchase?
